NCT06153784View on ClinicalTrials.gov

Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

603

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions
Thalassemia, Beta
Interventions
DRUG

Hydroxyurea and Thalidomide

Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients

Trial Locations (1)

Unknown

Children's Hospital Karachi, Karachi

All Listed Sponsors
lead

Children's Hospital Karachi

OTHER

NCT06153784 - Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients | Biotech Hunter | Biotech Hunter